Unsal Ayse Ipek Akyuz, Kocaturk Tolga, Gunel Ceren, Meteoglu Ibrahim, Omurlu Imran Kurt, Cakmak Harun, Demirci Buket
Department of Ophthalmology, Faculty of Medicine, Adnan Menderes University, 09100, Aydin, Turkey.
Department of Otorhinolaryngology, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey.
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1299-1304. doi: 10.1007/s00417-018-3988-7. Epub 2018 Apr 20.
Allergic conjunctivitis (AC) is a frequent and challenging disease in ophthalmology practice. Cell protective effect of Pycnogenol® (PYC) depends on its antioxidant and anti-inflammatory properties. The aim of the study is to investigate the effect of PYC on an experimental AC model.
Ovalbumin and Al(OH) were given seven times intraperitoneally (i.p.) every other day and ovalbumin installed everyday directly on conjunctiva to create an AC rat model. Then, PYC (3 or 10 mg/kg i.p.) was applied in the study groups. Control rats were given adjuvant Al(OH) i.p. and topical saline on conjunctiva. A negative control group in which only PYC (10 mg/kg/7 days) was administered i.p. and an AC positive control group which have been given dexamethasone (1 mg/kg/7 days) was created. Mast cells were counted with a microscope; histological evaluation was performed with H-E and toluidine blue, mast cell tryptase, and TNF-α and TGF-β staining.
Pycnogenol treatment alone did not show any detrimental effect. Mast cell count (MCC) decreased in both dexamethasone and 10 mg/kg given PYC treatment groups compared to positive control group and these results were statistically significant (MCC 1.85 ± 0.69, p < 0.001; 2.42 ± 0.53, p = 0.003). Negative staining with TGF-β and weak focal staining with TNF-α were the common findings of dexamethasone and PYC treatment groups.
The animal model of AC was successfully developed by using aforementioned way. PYC is a safe herbal product and it has alleviated the findings of ovalbumin-induced AC-similar to dexamethasone-histologically in this experimental model. These results are promising for the future of AC treatment.
过敏性结膜炎（AC）是眼科临床中常见且具有挑战性的疾病。碧萝芷®（PYC）的细胞保护作用取决于其抗氧化和抗炎特性。本研究旨在探讨PYC对实验性AC模型的影响。
每隔一天腹腔注射（i.p.）卵清蛋白和氢氧化铝（Al(OH)）共7次，每天直接将卵清蛋白滴入结膜以建立AC大鼠模型。然后，在研究组中应用PYC（3或10mg/kg，腹腔注射）。对照组大鼠腹腔注射佐剂Al(OH)并在结膜局部应用生理盐水。设立仅腹腔注射PYC（10mg/kg/7天）的阴性对照组和给予地塞米松（1mg/kg/7天）的AC阳性对照组。用显微镜计数肥大细胞；采用苏木精-伊红（H-E）染色、甲苯胺蓝染色、肥大细胞类胰蛋白酶染色以及肿瘤坏死因子-α（TNF-α）和转化生长因子-β（TGF-β）染色进行组织学评估。
单独使用碧萝芷治疗未显示出任何有害影响。与阳性对照组相比，地塞米松组和给予10mg/kg PYC治疗组的肥大细胞计数（MCC）均降低，且这些结果具有统计学意义（MCC 1.85±0.69，p＜0.001；2.42±0.53，p = 0.003）。TGF-β阴性染色和TNF-α弱阳性局灶性染色是地塞米松组和PYC治疗组的共同表现。
通过上述方法成功建立了AC动物模型。在该实验模型中，PYC是一种安全的草药产品，在组织学上它与地塞米松一样减轻了卵清蛋白诱导的AC症状。这些结果为AC治疗的未来发展带来了希望。
